A lawsuit over generic versions of Allergan PLC’s Alzheimer’s drug Namenda XR (memantine extended-release) is challenging how FDA determines whether an abbreviated new drug application (ANDA) sponsor has forfeited generic marketing exclusivity.
In a Jan. 27 complaint, Amneal Pharmaceuticals LLC asks the US District Court for the District of Columbia to set aside FDA’s determination that it forfeited 180-day...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?